Harbour BioMed Co. Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT04092907
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed US, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

hbm9161 (7 trials)

tanfanercept (2 trials)

Drugs in Phase 1 Trials (6)

hbm1020 (1 trial)

hbm4003 (5 trials)

hbm 7008 (1 trial)

hbm9378 (1 trial)

pembrolizumab (keytruda) (1 trial)

toripalimab (LOQTORZ) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Myasthenia Gravis (Phase 2)

Neoplasms (Phase 1)

Neuromyelitis Optica (Phase 1)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 8